These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19432937)

  • 41. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated.
    Ogino S; Nagakura T; Okubo K; Sato N; Takahashi M; Ishikawa T
    Int Arch Allergy Immunol; 2009; 149(3):239-45. PubMed ID: 19218816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.
    Constantine GM; Bressler PB; Petroni D; Metcalfe DD; Carter MC
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1314-1316. PubMed ID: 30149096
    [No Abstract]   [Full Text] [Related]  

  • 43. Elevated baseline serum tryptase, mastocytosis and anaphylaxis.
    Müller UR
    Clin Exp Allergy; 2009 May; 39(5):620-2. PubMed ID: 19400907
    [No Abstract]   [Full Text] [Related]  

  • 44. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
    Corren J; Shapiro G; Reimann J; Deniz Y; Wong D; Adelman D; Togias A
    J Allergy Clin Immunol; 2008 Feb; 121(2):506-11. PubMed ID: 18269927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy for hymenoptera venom and biting insect hypersensitivity.
    Müller UR; Golden DB; Demarco PJ; Lockey RF
    Clin Allergy Immunol; 2004; 18():541-59. PubMed ID: 15042934
    [No Abstract]   [Full Text] [Related]  

  • 46. [Hypersensitivity to honey bee venom].
    Adamek-Guzik T
    Przegl Lek; 1994; 51(4):161-6. PubMed ID: 8058985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful use of omalizumab for prevention of fire ant anaphylaxis.
    Tartibi HM; Majmundar AR; Khan DA
    J Allergy Clin Immunol; 2010 Sep; 126(3):664-5. PubMed ID: 20673977
    [No Abstract]   [Full Text] [Related]  

  • 48. Idiopathic anaphylaxis successfully treated with omalizumab.
    Jones JD; Marney SR; Fahrenholz JM
    Ann Allergy Asthma Immunol; 2008 Nov; 101(5):550-1. PubMed ID: 19055211
    [No Abstract]   [Full Text] [Related]  

  • 49. Omalizumab in the treatment of adult patients with mastocytosis: A systematic review.
    Jendoubi F; Gaudenzio N; Gallini A; Negretto M; Paul C; Bulai Livideanu C
    Clin Exp Allergy; 2020 Jun; 50(6):654-661. PubMed ID: 32107810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hereditary alpha tryptasemia in identical twins.
    Bethea LH; Tuano KS; Seth N; Chinen J
    Ann Allergy Asthma Immunol; 2021 Oct; 127(4):503-504. PubMed ID: 34157394
    [No Abstract]   [Full Text] [Related]  

  • 51. Pilot trial evaluating the treatment of focal vitiligo with intralesional honeybee venom injection.
    AlGhamdi KM; Khurrum H
    J Cutan Med Surg; 2012; 16(6):385-6. PubMed ID: 23149190
    [No Abstract]   [Full Text] [Related]  

  • 52. Combination of omalizumab and bee venom immunotherapy: does it work?
    Yılmaz İ; Bahçecioğlu SN; Türk M
    Asia Pac Allergy; 2018 Jan; 8(1):e2. PubMed ID: 29423369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Omalizumab and Mast Cell Disorders: Are We There Yet?
    Weiler CR
    J Allergy Clin Immunol Pract; 2019; 7(7):2396-2397. PubMed ID: 31495435
    [No Abstract]   [Full Text] [Related]  

  • 54. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon.
    Pardini S; Bosincu L; Bonfigli S; Dore F; Longinotti M
    Acta Haematol; 1991; 85(4):220. PubMed ID: 1853687
    [No Abstract]   [Full Text] [Related]  

  • 55. Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab.
    Weiss SL; Hyman JB; Carlson GS; Coop CA
    Fed Pract; 2021 Jan; 38(1):44-48. PubMed ID: 33574649
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome.
    da Silva EN; Randall KL
    J Allergy Clin Immunol Pract; 2013; 1(6):687-8. PubMed ID: 24565720
    [No Abstract]   [Full Text] [Related]  

  • 57. Utilizing Biologics in Drug Desensitization.
    Yang BC; Castells MC
    Curr Allergy Asthma Rep; 2023 Jan; 23(1):1-11. PubMed ID: 36445652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Honey bee venom re-challenge during specific immunotherapy: prolonged cardio-pulmonary resuscitation allowed survival in a case of near fatal anaphylaxis.
    Micaletto S; Ruetzler K; Bruesch M; Schmid-Grendelmeier P
    Allergy Asthma Clin Immunol; 2022 Jun; 18(1):44. PubMed ID: 35655287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis.
    Gülsen A; Ruëff F; Jappe U
    Allergol Select; 2021; 5():128-132. PubMed ID: 33733040
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of biologics in allergen immunotherapy.
    Pfützner W; Schuppe M
    Allergol Select; 2021; 5():108-118. PubMed ID: 33634221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.